News Releases

September 26, 2025

Merck Animal Health Presents New Data Demonstrating the Safety, Efficacy and Quick Onset of Injectable Formulation of BRAVECTO® (fluralaner) at World Small Animal Veterinary Association Congress

Additional educational symposia offer the latest information on vector-borne diseases, infectious diseases and treatment and prevention protocols Rahway, NJ, September 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will present multiple […]

September 25, 2025

Merck Animal Health Strengthens Its Dedication to Rabies Elimination with 7 Millionth Vaccine Donation Through the Afya Program

RAHWAY, N.J., Sept. 26, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has donated more than seven million NOBIVAC® rabies vaccines through the Company’s Afya Program, since it was founded. “Communities experiencing ongoing […]

September 12, 2025

Merck Animal Health Presented New Data on NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for Dogs at the 2025 European Veterinary Dermatology Congress

RAHWAY, N.J., September 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate […]

August 18, 2025

Merck Animal Health Presents New Data Highlighting Commitment to the Development and Study of Parasite Prevention and Treatment for Dogs at the 2025 World Association for the Advancement of Veterinary Parasitology Congress

Data to showcase depth and breadth of the BRAVECTO® (fluralaner) portfolio including the injectable and oral endectocide combination formulations RAHWAY, N.J., August 18, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it will […]

July 24, 2025

European Commission Approves NUMELVI™ (atinvicitinib) Tablets for Dogs

NUMELVI from Merck Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United […]

July 10, 2025

FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health

12-Month Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products RAHWAY, N.J., July 10, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and […]

June 12, 2025

Merck Animal Health Receives Positive Opinion from CVMP for NOBIVAC®L6 and NOBIVAC® LoVo L6 Vaccines for Use in Dogs Against Leptospirosis

RAHWAY, N.J., June 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® […]

June 12, 2025

Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs

If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States […]

May 2, 2025

FDA Approves Merck Animal Health’s MOMETAMAX SINGLE™ to Treat Otitis Externa in Dogs

The leading manufacturer of otic treatments expands portfolio with the only FDA-approved, one dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens RAHWAY, N.J., May 02, 2025 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced […]

February 11, 2025

Merck Animal Health Wins 2024 S&P Global Award for Best New Companion Animal Product for injectable formulation of BRAVECTO® (fluralaner)

Parasiticide Treatment for Dogs Offers Unrivaled Duration of Flea and Tick Protection Compared to Existing Products Rahway, N.J., February 11, 2025 – Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that S&P Global Animal Health awarded the injectable formulation of BRAVECTO® (fluralaner) the 2024 Best New Companion […]